TherapeuticsMD (TXMD) Raw Materials (2012 - 2022)

TherapeuticsMD has reported Raw Materials for 11 years, with the latest figure at $1.9 million in Q3 2022.

• For the quarter ending Q3 2022, Raw Materials fell 44.19% year-over-year to $1.9 million; the trailing twelve-month figure through Sep 2022 stood at $1.9 million (down 44.19% YoY), and the FY2021 full-year result was $3.0 million, down 18.84% from the prior year.
• Raw Materials for Q3 2022 stood at $1.9 million, up from $434000.0 in the prior quarter.
• The five-year high for Raw Materials was $5.7 million in Q4 2019, with the low at $19400.0 in Q4 2018.
• Historically, Raw Materials has averaged $3.0 million across 5 years, with a median of $3.6 million in 2020.
• Annual changes were most pronounced in 2019 — Raw Materials jumped 29290.45% — and 2022, when it plunged 90.43%.
• TherapeuticsMD's Raw Materials stood at $19400.0 in 2018, then jumped by 29290.45% to $5.7 million in 2019, then slumped by 34.27% to $3.7 million in 2020, then declined by 18.84% to $3.0 million in 2021, then sank by 36.03% to $1.9 million in 2022.
• The last three Raw Materials figures came in at $1.9 million (Q3 2022), $434000.0 (Q2 2022), and $4.4 million (Q1 2022), per Business Quant data.